Ad Header



The Pulse of the Pharmaceutical Industry

EU approves first gene therapy for children

Written by: | | Dated: Friday, May 27th, 2016


Called Strimvelis, it is designed for a tiny number of children with ADA Severe Combined Immune Deficiency (ADA-SCID). SCID is sometimes known as “bubble baby” disease, since those born with it have immune systems so weak they must live in germ-free environments.

Strimvelis is the second gene therapy to be approved in Europe, after UniQure’s Glybera, which treats a rare adult blood disorder.

Glybera made history in 2014 as the first drug to carry a $1 million price tag. GSK has not so far revealed how much its product will cost but a source close to the company said last month it would be “very significantly less than $1 million”.

The EU approval for GSK’s treatment had been expected, following a positive opinion from the European Medicines Agency last month.

The U.S. Food and Drug Administration has yet to approve any gene therapies but a growing number of U.S. biotech companies have products in development.


(Reporting by Ben Hirschler; editing by Adrian Croft)

Source: Reuters Health

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom